Ridgefield, Conn.
Boehringer Ingelheim broke ground on a $65 million research and development facility in Ridgefield, Conn., in November of 2011. The 72,000-sf facility will support the production of active pharmaceutical ingredients for early stage product development. Completion is expected in 2014. A $42.5 million safety assessment building is also under construction. Boehringer Ingelheim is based in Germany.
